Skip to main content

BioAge Labs, Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

BIOA$5.78+1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share information)

Three Months Ended · Six Months Ended
June 30,June 30,
2025202420252024
Collaboration revenue$2,412$—$3,863$—
Operating expenses:
Research and development$19,844$10,471$30,953$19,792
General and administrative7,3394,79814,1278,290
Total operating expenses27,18315,26945,08028,082
Loss from operations(24,771)(15,269)(41,217)(28,082)
Other income (expense)
Interest expense(201)(443)(456)(1,660)
Interest and other income (expense), net3,4202,2017,1343,497
Gain (loss) from changes in fair value of warrants(11)(70)48(78)
Loss on extinguishment of debt———(250)
Total other income (expense), net3,2081,6886,7261,509
Net loss$(21,563)$(13,581)$(34,491)$(26,573)
Net loss per share attributable to common stockholders, basic and diluted$(0.60)$(7.94)$(0.96)$(15.70)
Weighted-average common shares outstanding, basic and dilutive35,850,0371,711,00535,850,0371,692,238
Comprehensive loss:
Net loss(21,563)(13,581)(34,491)(26,573)
Other comprehensive income (loss):
Unrealized holding gains on available-for-sale investments——29—
Foreign currency translation adjustment(52)(18)(62)3
Total other comprehensive income (loss):(52)(18)(33)3
Total comprehensive loss$(21,615)$(13,599)$(34,524)$(26,570)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.